vorinostat

FDA Drug Profile — ZOLINZA

Drug Details

Generic Name
vorinostat
Brand Names
ZOLINZA
Application Number
NDA021991
Sponsor
Patheon Inc.
NDC Codes
2
Dosage Forms
CAPSULE
Routes
ORAL
Active Ingredients
VORINOSTAT

Indications and Usage

1 INDICATIONS AND USAGE ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. ( 1 )